Jan 31,2023 C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors read more >>
Jan 27,2023 Twist Bioscience Begins Shipping Commercial Product from Synthetic DNA Manufacturing Factory of the Future read more >>
Jan 05,2023 Immune-Onc Therapeutics Announces Close of Series B Extension Financing, Bringing Total Round to $131 Million read more >>
Dec 31,2022 ONCOC4 ANNOUNCES FIRST PATIENT DOSED IN PRESERVE-004, A PHASE 2 CLINICAL TRIAL OF ONC-392 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER read more >>
Dec 15,2022 Avirmax CMC Inc. Successfully Manufactured and Delivered to a Client the First Lot of rAAV Drug Product for a Monkey Toxicology Study read more >>
Nov 30,2022 KBP Presents Results of the Hepatic Impairment Study and Drug-Drug Interaction Study of Ocedurenone (KBP-5074) at ASN Kidney Week 2022 read more >>
Nov 29,2022 Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC read more >>